# ë°°ê²½ ìë£Œ: Session 4 - Antibiotic Development

**ì„¸ì…˜**: Session 4: Antibiotic Development
**ì—°ì‚¬**: Jaehoon Yu (CAMP Therapeutics), Hee-Jong Hwang (A&J Science), Yan Lee (Seoul Natl. Univ.)
**ì¼ì‹œ**: 2025ë…„ 10ì›” 30ì¼ (ëª©) 16:40-17:55
**ì¥ì†Œ**: ì„±ê· ê´€ëŒ€í•™êµ ì˜ê³¼ëŒ€í•™, AI ê°•ì˜ì‹¤ 3304

**ì¤‘ìš”ë„**: â­â­â­â­â­ (98/100ì )

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

**1. ì‹¤ì œ ì‹ ì•½ í›„ë³´ ë¬¼ì§ˆì„ ë‹¤ë£¬ë‹¤ (í•™ê³„ë¥¼ ë„˜ì–´ ì‚°ì—…ìœ¼ë¡œ)**
- CAMP Therapeutics: methotrexate-CPP conjugate (preclinical)
- A&J Science: Thiopeptide antibiotics (GMP ìƒì‚°, ì„ìƒ ì¤€ë¹„)
- Seoul National Univ.: pH-responsive peptides (in vivo íš¨ê³¼ í™•ì¸)
- ëª¨ë‘ ì‹¤ì œ ê°œë°œ ë‹¨ê³„ (ë…¼ë¬¸ì´ ì•„ë‹Œ ì œí’ˆ)

**2. ê·¸ëŒìŒì„±ê·  ë¬¸ì œë¥¼ ì •ë©´ ëŒíŒŒí•œë‹¤**
- ì™¸ë§‰(outer membrane) = í•­ìƒì œ ê°œë°œì˜ ìµœëŒ€ ë‚œì œ
- 2024ë…„ FDA ìŠ¹ì¸ í•­ìƒì œ: ê·¸ëŒìŒì„±ê· ìš© ê±°ì˜ ì—†ìŒ
- ì´ ì„¸ì…˜ì˜ 3ê°€ì§€ ì ‘ê·¼: ëª¨ë‘ ê·¸ëŒìŒì„±ê·  íƒ€ê²ŸíŒ…
  - CPP (cell-penetrating peptide): ì™¸ë§‰ í†µê³¼
  - Thiopeptides: ë¦¬ë³´ì†œ í‘œì  (ê´‘ë²”ìœ„)
  - Hinged peptides: pH ë³€í™”ë¡œ ì„ íƒì  í™œì„±í™”

**3. ì°¨ì„¸ëŒ€ í•­ìƒì œì˜ 3ê°€ì§€ í•µì‹¬ ì „ëµì„ ì œì‹œí•œë‹¤**
- **Drug repurposing**: Methotrexate (í•­ì•”ì œ) â†’ Antibiotic
- **Natural products**: Thiopeptides (í•´ì–‘ ë¯¸ìƒë¬¼)
- **Rational design**: pH-responsive peptides (ê°ì—¼ ë¶€ìœ„ íŠ¹ì´ì )

**4. í¬ë‹¥/ì‚°ì—…ê³„ ì§„ë¡œì— ì§ì ‘ ë„ì›€ì´ ëœë‹¤**
- ë°”ì´ì˜¤í… ì°½ì—… ì‚¬ë¡€ (CAMP, A&J)
- ëŒ€í•™-ì‚°ì—… ì—°ê³„ (Seoul Nat'l - ê¸°ìˆ ì´ì „)
- Regulatory pathway (FDA, MFDS) ê²½í—˜ ê³µìœ 

---

## ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (ì„¸ì…˜ ì „ì²´)

### ì´ ì„¸ì…˜ì€ ì‰½ê²Œ ë§í•˜ë©´...

**í•œ ì¤„ ìš”ì•½**: "ê·¸ëŒìŒì„±ê· ì„ ì¡ê¸° ì–´ë ¤ìš´ ì´ìœ ëŠ” 'ì™¸ë§‰'ì¸ë°, ê·¸ ì™¸ë§‰ì„ ëš«ê±°ë‚˜, ìš°íšŒí•˜ê±°ë‚˜, ì„ íƒì ìœ¼ë¡œ ê³µëµí•˜ëŠ” 3ê°€ì§€ ì‹ ì•½ í›„ë³´ë¥¼ ì†Œê°œ"

### ğŸ¬ ê·¸ëŒìŒì„±ê· ê³¼ì˜ ì „ìŸ - ì´ì•¼ê¸°ë¡œ ì´í•´í•˜ê¸°

**[1ì¥: ì™¸ë§‰ì˜ ì €ì£¼ - Why Gram-Negative Bacteria Are Hard to Kill]**

**ë°°ê²½**: í•­ìƒì œì˜ "ë² ë¥¼ë¦° ì¥ë²½"

```
ê·¸ëŒì–‘ì„±ê·  vs. ê·¸ëŒìŒì„±ê· :

ê·¸ëŒì–‘ì„±ê·  (S. aureus, Streptococcus):
- ì„¸í¬ë²½: Peptidoglycan (PG) ë‘êº¼ì›€ (20-80 nm)
- ì™¸ë§‰: ì—†ìŒ
- í•­ìƒì œ íˆ¬ê³¼: ìƒëŒ€ì ìœ¼ë¡œ ì‰¬ì›€
â†’ ë§ì€ í•­ìƒì œ ê°œë°œ ì„±ê³µ (penicillin, vancomycin, daptomycin)

ê·¸ëŒìŒì„±ê·  (E. coli, P. aeruginosa, K. pneumoniae):
- ì„¸í¬ë²½: PG ì–‡ìŒ (7-8 nm)
- ì™¸ë§‰ (OM): ìˆìŒ!
  â†’ Lipopolysaccharide (LPS): ìŒì „í•˜ ë”
  â†’ Porin channels: í¬ê¸°/ì „í•˜ ì„ íƒì„±
  â†’ Efflux pumps: ì•½ë¬¼ ë°°ì¶œ

- í•­ìƒì œ íˆ¬ê³¼: ë§¤ìš° ì–´ë ¤ì›€
â†’ ì‹ ì•½ ê°œë°œ ê±°ì˜ ì—†ìŒ (2010-2020: FDA ìŠ¹ì¸ ê·¸ëŒìŒì„±ê·  í•­ìƒì œ 3ê°œë¿)
```

**ì „í™˜ì **: ì™¸ë§‰ì„ ì–´ë–»ê²Œ ëŒíŒŒí•  ê²ƒì¸ê°€?

```
ë¬¸ì œ: ì™¸ë§‰ì˜ 3ì¤‘ ë°©ì–´ì„ 
1. LPS (lipopolysaccharide)
   - ìŒì „í•˜ â†’ ì–‘ì „í•˜ í•­ìƒì œ ì •ì „ê¸° ìƒí˜¸ì‘ìš©
   - í•˜ì§€ë§Œ ì™„ë²½í•œ ì¥ë²½ì€ ì•„ë‹˜ (ì¼ë¶€ëŠ” í†µê³¼)

2. Porin channels
   - í¬ê¸° ì œí•œ: ~600 Da
   - ì¹œìˆ˜ì„± ë¶„ìë§Œ í†µê³¼
   â†’ ëŒ€ë¶€ë¶„ì˜ í•­ìƒì œ (ì¹œìœ ì„±, í° ë¶„ìëŸ‰) ì°¨ë‹¨

3. Efflux pumps
   - AcrAB-TolC (E. coli), MexAB-OprM (P. aeruginosa)
   - ì„¸í¬ ë‚´ ë“¤ì–´ì˜¨ ì•½ë¬¼ë„ ë‹¤ì‹œ ë°°ì¶œ
   â†’ ë‚´ì„±ì˜ ì£¼ìš” ë©”ì»¤ë‹ˆì¦˜

ê¸°ì¡´ í•´ê²°ì±…:
- Polymyxin (colistin): LPSì™€ ê²°í•©, ì™¸ë§‰ íŒŒê´´
  â†’ ë¬¸ì œ: ë…ì„± (ì‹ ë…ì„±), ë‚´ì„± ì¶œí˜„
- Carbapenem: Porin í†µê³¼ ê°€ëŠ¥
  â†’ ë¬¸ì œ: ë‚´ì„± (carbapenemase)

â†’ ìƒˆë¡œìš´ í•´ê²°ì±… í•„ìš”!
```

**[ë°œê²¬/ì˜ë¯¸]**:

1. **Jaehoon Yu (CAMP)ì˜ ì ‘ê·¼: "Trojan Horse" ì „ëµ**
   - Methotrexate (MTX): í•­ì•”ì œ (DHFR ì–µì œì œ)
   - ë¬¸ì œ: ê·¸ëŒìŒì„±ê·  ì™¸ë§‰ í†µê³¼ ëª»í•¨
   - í•´ê²°: Cell-Penetrating Peptide (CPP) ê²°í•©
     â†’ 1403 peptide: Proline-rich, helical structure
     â†’ ì™¸ë§‰ í†µê³¼ â†’ cytosol ë„ë‹¬
   - ê²°ê³¼: E. coli NDM1 (carbapenem ë‚´ì„±) ì‚¬ë©¸
     - MIC: 15 mg/kg doseë¡œ 10âµ-fold CFU â†“
   - **ì˜ë¯¸**: ê¸°ì¡´ ì•½ë¬¼ (FDA ìŠ¹ì¸) ì¬í™œìš© ê°€ëŠ¥

2. **Hee-Jong Hwang (A&J)ì˜ ì ‘ê·¼: ìì—°ì˜ ë¬´ê¸°ê³ **
   - Thiopeptides: í•´ì–‘ ë¯¸ìƒë¬¼ ì²œì—°ë¬¼
   - íŠ¹ì§•: í™©(S) í•¨ìœ  ê³ ë¦¬í˜• í©íƒ€ì´ë“œ
     â†’ Ribosome (50S subunit) í‘œì 
     â†’ Protein synthesis ì–µì œ
   - ì˜ˆ: Micrococcin P2 derivatives
     - C. difficile (ì¥ë…ì†Œ): MIC < 1 Î¼g/mL
     - NTM (M. avium, P. aeruginosa): íš¨ê³¼ í™•ì¸
   - ë¬¸ì œ: ìˆ˜ìš©ì„± ë‚®ìŒ, ë…ì„±
   - í•´ê²°: í™”í•™ êµ¬ì¡° ìµœì í™”
     â†’ 200,000ë°° ìˆ˜ìš©ì„± í–¥ìƒ (decagram scale)
   - **ì˜ë¯¸**: ìƒˆë¡œìš´ í™”í•™ scaffold, ê´‘ë²”ìœ„ ìŠ¤í™íŠ¸ëŸ¼

3. **Yan Lee (Seoul Nat'l)ì˜ ì ‘ê·¼: ìŠ¤ë§ˆíŠ¸ í©íƒ€ì´ë“œ**
   - Hinged Amphipathic Peptides (HAP)
   - ì„¤ê³„: Lysine â†’ Histidine ì¹˜í™˜
     â†’ pH 7.4 (í˜ˆì•¡): ì¤‘ì„± (ë¹„í™œì„±)
     â†’ pH 6.5 (ê°ì—¼ ë¶€ìœ„): ì–‘ì „í•˜ (í™œì„±)
   - ë©”ì»¤ë‹ˆì¦˜:
     â†’ pH â†“ â†’ Histidine protonation â†’ ì–‘ì „í•˜ â†‘
     â†’ Bacterial membrane ê²°í•© â†’ disruption
   - íš¨ê³¼:
     - A. baumannii skin infection: ë³‘ë³€ í¬ê¸° â†“
     - E. coli NDM-1 bacteremia: ìƒì¡´ìœ¨ â†‘
   - **ì˜ë¯¸**: ë¶€ìœ„ íŠ¹ì´ì , ì„ íƒë…ì„± ë‚®ìŒ

**ê²°ë¡ **: "ê·¸ëŒìŒì„±ê· ì„ ì¡ìœ¼ë ¤ë©´, ì™¸ë§‰ì„ 'ëš«ê±°ë‚˜'(CPP), 'ìš°íšŒí•˜ê±°ë‚˜'(Ribosome í‘œì ), 'ì¡°ê±´ë¶€ë¡œ í™œì„±í™”'(pH-responsive) í•´ì•¼ í•œë‹¤."

---

**[2ì¥: Drug Repurposing - ì˜¤ë˜ëœ ì•½ì˜ ìƒˆë¡œìš´ ìš©ë„]**

**ì£¼ìš” ê°œë… 1: Methotrexate (MTX)ì˜ ì´ì¤‘ ìƒí™œ**

```
MTXì˜ ì›ë˜ ìš©ë„:
- í•­ì•”ì œ: Leukemia, lymphoma ì¹˜ë£Œ
- ë©´ì—­ì–µì œì œ: ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, psoriasis
- ë©”ì»¤ë‹ˆì¦˜: Dihydrofolate reductase (DHFR) ì–µì œ
  â†’ Tetrahydrofolate (THF) í•©ì„± â†“
  â†’ Purine, Pyrimidine í•©ì„± â†“
  â†’ DNA í•©ì„± ì°¨ë‹¨ â†’ ì„¸í¬ ì„±ì¥ ì •ì§€

ì„¸ê· ì—ë„ DHFR ìˆìŒ:
- E. coli, P. aeruginosa, K. pneumoniae: DHFR í•„ìˆ˜
- MTXê°€ ì„¸ê·  DHFRë„ ì–µì œ ê°€ëŠ¥ (in vitro)
- ë¬¸ì œ: ì™¸ë§‰ í†µê³¼ ëª»í•¨ â†’ MIC ë§¤ìš° ë†’ìŒ (>256 Î¼g/mL)

â†’ CPPë¡œ í•´ê²°
```

**ì£¼ìš” ê°œë… 2: Cell-Penetrating Peptide (CPP)**

```
CPPë€?
- 10-30 ì•„ë¯¸ë…¸ì‚° ì§§ì€ í©íƒ€ì´ë“œ
- íŠ¹ì§•: ì–‘ì „í•˜ ë§ìŒ (Arg, Lys) ë˜ëŠ” ì–‘ì¹œë§¤ì„±
- ê¸°ëŠ¥: ì„¸í¬ë§‰ í†µê³¼ ì´‰ì§„
  â†’ ì•½ë¬¼, DNA, protein ì „ë‹¬

ì—­ì‚¬:
- 1988: TAT peptide (HIV-1 Tat protein ìœ ë˜)
- 1990s: Penetratin, pAntp
- 2000s: í•©ì„± CPP (oligo-arginine, R9)

ë©”ì»¤ë‹ˆì¦˜ (ë…¼ìŸ ì¤‘):
1. Direct penetration: ë§‰ì„ ì§ì ‘ ëš«ìŒ
2. Endocytosis: ì„¸í¬ë‚´ì´ì… â†’ endosome escape
3. Transient pore: ì¼ì‹œì  êµ¬ë© í˜•ì„±

ê·¸ëŒìŒì„±ê·  ì™¸ë§‰ í†µê³¼:
- ê¸°ì¡´ CPP: ëŒ€ë¶€ë¶„ ì§„í•µ ì„¸í¬ìš©
- 1403 peptide (CAMPì˜ ê°œë°œ):
  â†’ Proline-rich, helical
  â†’ LPSì™€ ìƒí˜¸ì‘ìš©
  â†’ Porin ìš°íšŒ, ì™¸ë§‰ í†µê³¼
```

**Jaehoon Yuì˜ í˜ì‹ : MTX-CPP Conjugate**

```
ì„¤ê³„:
- MTX (DHFR ì–µì œì œ)
- Linker (cleavable, e.g., ester bond)
- 1403 CPP (proline-rich, ì™¸ë§‰ í†µê³¼)

ë©”ì»¤ë‹ˆì¦˜:
1. CPPê°€ ì™¸ë§‰ í†µê³¼ (E. coli)
2. Periplasm ë„ë‹¬
3. Linker cleavage (esterase)
4. MTX ë°©ì¶œ
5. MTXê°€ cytosol ì´ë™ â†’ DHFR ì–µì œ
6. DNA í•©ì„± ì°¨ë‹¨ â†’ ì„¸ê·  ì‚¬ë©¸

In vitro íš¨ê³¼:
- E. coli NDM1 (carbapenem ë‚´ì„±): MIC 16 Î¼g/mL (MTX alone >256)
- P. aeruginosa: MIC 32 Î¼g/mL

In vivo íš¨ê³¼ (ë§ˆìš°ìŠ¤ bacteremia):
- E. coli NDM1 ê°ì—¼ (ë³µê°•)
- MTX-CPP íˆ¬ì—¬ (15 mg/kg, i.p.)
- ê²°ê³¼: CFU 10âµ-fold â†“, ìƒì¡´ìœ¨ 100%

ë…ì„±:
- MTX alone: ê³¨ìˆ˜ì–µì œ, ê°„ë…ì„± (í™”í•™ìš”ë²• ìš©ëŸ‰)
- MTX-CPP: ë‚®ì€ ìš©ëŸ‰ (15 mg/kg), ì„ íƒë…ì„±
- ì •ìƒ ì„¸í¬: CPP ì—†ìœ¼ë©´ MTX ì§„ì… ì–´ë ¤ì›€

â†’ ì¹˜ë£Œ ì§€ìˆ˜ (TI): MTX aloneë³´ë‹¤ 10ë°° ì´ìƒ í–¥ìƒ
```

**ì˜ë¯¸**:

"FDA ìŠ¹ì¸ ì•½ë¬¼ (MTX)ì„ ì¬í™œìš©í•˜ë©´:
1. ì•ˆì „ì„± ë°ì´í„° ì´ë¯¸ ìˆìŒ (50ë…„ ì‚¬ìš© ì—­ì‚¬)
2. ê°œë°œ ê¸°ê°„ ë‹¨ì¶• (10ë…„ â†’ 3-5ë…„?)
3. ë¹„ìš© ì ˆê° (ì‹ ì•½ ê°œë°œ ëŒ€ë¹„ 1/10)

CPP ê¸°ìˆ ì€ ë‹¤ë¥¸ ì•½ë¬¼ì—ë„ ì ìš© ê°€ëŠ¥:
- Fluoroquinolone-CPP (ë‚´ì„±ê· )
- Aminoglycoside-CPP (biofilm)
- Antifungal-CPP (Candida ì™¸ë§‰)"

---

**[3ì¥: Natural Products - ìì—°ì´ ë§Œë“  í•­ìƒì œ]**

**ì£¼ìš” ê°œë… 3: Thiopeptidesì˜ ì¬ë°œê²¬**

```
Thiopeptidesë€?
- ì²œì—° í•­ìƒì œ (1940s ë°œê²¬)
- ìƒì‚°: ë°©ì„ ê·  (Streptomyces), í•´ì–‘ ë¯¸ìƒë¬¼
- êµ¬ì¡°: í™©(S) í•¨ìœ  ê³ ë¦¬í˜• í©íƒ€ì´ë“œ (30-50 amino acids)
  â†’ Thiazole, oxazole rings
  â†’ Macrocyclic structure

ëŒ€í‘œ ë¬¼ì§ˆ:
- Micrococcin (1948 ë°œê²¬)
- Thiostrepton (ìˆ˜ì˜ìš©)
- Nosiheptide
- LFF571 (Merck, Phase 2 for C. difficile)

ë©”ì»¤ë‹ˆì¦˜:
- 50S ribosomal subunit ê²°í•©
- L11 protein + 23S rRNA ì¸ê·¼
- Elongation factor (EF-G, EF-Tu) ì–µì œ
â†’ Protein synthesis ì°¨ë‹¨

ì™œ ìŠí˜€ì¡Œë‚˜?
1. ìˆ˜ìš©ì„± ë‚®ìŒ (ì„ìƒ íˆ¬ì—¬ ì–´ë ¤ì›€)
2. ì´ˆê¸° ë…ì„± ë°ì´í„° (ë™ë¬¼ ì‹¤í—˜)
3. ë‹¤ë¥¸ í•­ìƒì œ ê°œë°œ ì„±ê³µ (Î²-lactam, fluoroquinolone)

ì™œ ì¬ë¶€ìƒ?
1. AMR ìœ„ê¸° (ì‹ ê·œ scaffold í•„ìš”)
2. í™”í•™ í•©ì„± ê¸°ìˆ  ë°œì „ (ìˆ˜ì • ê°€ëŠ¥)
3. C. difficile ì¦ê°€ (thiopeptides íš¨ê³¼ì )
```

**Hee-Jong Hwangì˜ ì ‘ê·¼: Thiopeptides ìµœì í™”**

```
A&J Science í”Œë«í¼:
1. ì²œì—°ë¬¼ íƒìƒ‰
   - í•´ì–‘ ë¯¸ìƒë¬¼ (>10,000 strains)
   - Fermentation ìµœì í™”
   - Micrococcin P2 ë°œê²¬

2. êµ¬ì¡°-í™œì„± ê´€ê³„ (SAR) ì—°êµ¬
   - Core macrocycle: ìœ ì§€ (ribosome ê²°í•© í•„ìˆ˜)
   - Side chain: ìˆ˜ì • (ìˆ˜ìš©ì„±, PK ê°œì„ )
   - Derivatization: 200+ analogs

3. Lead optimization
   - Micrococcin P2 derivatives:
     â†’ ìˆ˜ìš©ì„±: 200,000ë°° í–¥ìƒ
     â†’ ìš©í•´ë„: < 1 Î¼g/mL â†’ 20 mg/mL
     â†’ GMP ìƒì‚°: decagram scale (10-100 g)

   - Activity spectrum:
     â†’ C. difficile: MIC 0.06-0.25 Î¼g/mL (vancomycin ëŒ€ë¹„)
     â†’ MRSA: MIC 2 Î¼g/mL
     â†’ P. aeruginosa: MIC 16 Î¼g/mL
     â†’ M. avium (NTM): MIC 8 Î¼g/mL

4. Preclinical development
   - PK/PD: Half-life 2-4h (ë§ˆìš°ìŠ¤), Cmax ì ì ˆ
   - Toxicity: MTD > 100 mg/kg (ë§ˆìš°ìŠ¤)
   - Efficacy (ë§ˆìš°ìŠ¤ C. diff ê°ì—¼):
     â†’ Vancomycin ëŒ€ë¹„ ë™ë“± ë˜ëŠ” ìš°ìˆ˜
     â†’ Recurrence ë‚®ìŒ (microbiome ë³´ì¡´)

5. Regulatory path
   - FDA orphan drug designation (C. difficile)
   - Phase 1 ì¤€ë¹„ ì¤‘ (2025-2026 ì˜ˆìƒ)
```

**ì‘ìš© ì‚¬ë¡€: C. difficile ì¹˜ë£Œ**

```
C. difficile infection (CDI):
- ë¯¸êµ­: ì—°ê°„ 500,000 cases, 29,000 deaths
- í•œêµ­: ì¦ê°€ ì¶”ì„¸ (ê³ ë ¹í™”, í•­ìƒì œ ì˜¤ë‚¨ìš©)
- ë¬¸ì œ: Vancomycin/metronidazole í›„ ì¬ë°œë¥  20-30%

Thiopeptidesì˜ ì¥ì :
1. Narrow spectrum:
   - C. difficileë§Œ ì£½ì„
   - ì •ìƒ ì¥ë‚´ ê· ì´ ë³´ì¡´ â†’ ì¬ë°œ â†“

2. Resistance ë‚®ìŒ:
   - Ribosome í‘œì  (conserved)
   - Cross-resistance ì ìŒ

3. ê²½êµ¬ íˆ¬ì—¬ ê°€ëŠ¥:
   - ì¥ì—ì„œ í¡ìˆ˜ ì•ˆ ë¨ (ìˆ˜ìš©ì„± ë‚®ìŒì´ ì˜¤íˆë ¤ ì¥ì )
   - Local action

â†’ Vancomycin ëŒ€ì²´ì œë¡œ ìœ ë§
```

**ì˜ë¯¸**:

"ìì—°ì€ ì´ë¯¸ ìˆ˜ë°±ë§Œ ë…„ ë™ì•ˆ í•­ìƒì œë¥¼ ë§Œë“¤ì–´ì™”ë‹¤.
ìš°ë¦¬ëŠ” ê·¸ê²ƒì„ 'ì°¾ì•„ì„œ', 'ê°œì„ í•´ì„œ', 'ì„ìƒì— ì ìš©'í•˜ë©´ ëœë‹¤.
ThiopeptidesëŠ” ìŠí˜€ì§„ ë³´ë¬¼ì´ì—ˆê³ , ì´ì œ ë‹¤ì‹œ ë¹›ì„ ë³¸ë‹¤."

---

**[4ì¥: Rational Design - ë§ì¶¤í˜• í•­ìƒì œ ì„¤ê³„]**

**ì£¼ìš” ê°œë… 4: pH-Responsive Peptides**

```
ê°ì—¼ ë¶€ìœ„ì˜ pH:
- ì •ìƒ ì¡°ì§: pH 7.4
- ê°ì—¼/ì—¼ì¦: pH 6.0-6.5
  â†’ ì´ìœ : Bacterial metabolism (lactic acid)
         Immune cell activity (acidification)
         Hypoxia (í˜ê¸°ì„± ëŒ€ì‚¬)

pH ë³€í™” í™œìš©:
- Tumor targeting (ì¢…ì–‘ë„ pH ë‚®ìŒ)
- Infection-specific activation

Histidine (His)ì˜ íŠ¹ì„±:
- pKa ~6.0 (physiological range)
- pH 7.4: ì¤‘ì„± (ë¹„ì–‘ì„±ìí™”)
- pH 6.0: ì–‘ì „í•˜ (ì–‘ì„±ìí™”)

â†’ Histidine-rich peptides = pH-responsive
```

**Yan Leeì˜ ì„¤ê³„: KLH3/KLH4 Peptides**

```
ê¸°ì¡´ peptide: KL4-9P (Lys-Leu rich)
- êµ¬ì¡°: Hinged amphipathic
  â†’ Hydrophobic face (Leu)
  â†’ Hydrophilic face (Lys)
- ë¬¸ì œ: í•­ìƒ ì–‘ì „í•˜ â†’ ë¹„ì„ íƒì 
  â†’ ì •ìƒ ì„¸í¬ ë…ì„± (Hemolysis)

Leeì˜ ìˆ˜ì •: Lys â†’ His ì¹˜í™˜
- KLH3: 3ê°œ Lys â†’ His
- KLH4: 4ê°œ Lys â†’ His

pH ì˜ì¡´ì„±:
- pH 7.4 (í˜ˆì•¡):
  â†’ His ì¤‘ì„± â†’ ì–‘ì „í•˜ ê°ì†Œ
  â†’ Membrane binding ì•½í•¨
  â†’ Hemolysis < 5%

- pH 6.5 (ê°ì—¼):
  â†’ His ì–‘ì„±ìí™” â†’ ì–‘ì „í•˜ ì¦ê°€
  â†’ Membrane binding ê°•í•¨
  â†’ Bacterial lysis â†‘

ë©”ì»¤ë‹ˆì¦˜:
1. Peptideê°€ ê°ì—¼ ë¶€ìœ„ ë„ë‹¬
2. pH ê°ì§€ (His protonation)
3. ì–‘ì „í•˜ ì¦ê°€ â†’ ì„¸ê· ë§‰ ê²°í•©
4. Membrane disruption (pore formation)
5. ì„¸ê·  ì‚¬ë©¸

In vitro activity:
- A. baumannii: MIC 4-8 Î¼g/mL (KLH3/4)
  vs. 16 Î¼g/mL (KL4-9P, pH 7.4ì—ì„œë„)
- E. coli: MIC 8-16 Î¼g/mL

In vivo efficacy:
- A. baumannii skin infection (ë§ˆìš°ìŠ¤):
  â†’ KLH3 topical: ë³‘ë³€ í¬ê¸° 70% â†“
  â†’ Superior to mupirocin

- E. coli NDM1 bacteremia:
  â†’ KLH3 i.p.: ìƒì¡´ìœ¨ 80% (control 20%)
  â†’ KL4-9P: ë…ì„±ìœ¼ë¡œ 60% ì‚¬ë§

Selectivity:
- pH 7.4: MPS (mononuclear phagocyte system) ì•ˆì „
- pH 6.5: ê°ì—¼ ë¶€ìœ„ë§Œ í™œì„±
â†’ Therapeutic index: 10ë°° í–¥ìƒ
```

**ì˜ë¯¸**:

"í•­ìƒì œëŠ” 'ì–¸ì œë‚˜ ON'ì¼ í•„ìš” ì—†ë‹¤.
ê°ì—¼ ë¶€ìœ„ì—ì„œë§Œ 'ìŠ¤ìœ„ì¹˜ ON'ë˜ë©´ ëœë‹¤.
pH-responsive peptidesëŠ” 'ìŠ¤ë§ˆíŠ¸ í•­ìƒì œ'ì˜ ì²« ê±¸ìŒì´ë‹¤.

ë¯¸ë˜ ì‘ìš©:
- Temperature-responsive (ì—´ ê°ì§€)
- Enzyme-responsive (protease cleavage)
- Light-responsive (photodynamic)

â†’ Precision antibioticsì˜ ì‹œëŒ€"

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (16:40-17:05): Repositioning methotrexate for an antibiotic by conjugating to Gram-negative specific penetrating peptide

**ì—°ì‚¬**: Jaehoon Yu, CEO (CAMP Therapeutics)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S4-1)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "í•­ì•”ì œ methotrexateì— 'ì™¸ë§‰ í†µê³¼ í©íƒ€ì´ë“œ'ë¥¼ ë¶™ì´ë©´, carbapenem ë‚´ì„± E. colië„ ì¡ëŠ” ì‹ ì•½ì´ ëœë‹¤"

**ìƒí™©**: Carbapenem ë‚´ì„±ì˜ ê³µí¬

```
Carbapenem:
- "Last-resort" í•­ìƒì œ
- ê·¸ëŒìŒì„±ê·  ì¤‘ì¦ ê°ì—¼ (íŒ¨í˜ˆì¦, íë ´)
- ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜:
  â†’ NDM-1, KPC, OXA-48 (carbapenemase)
  â†’ Metallo-Î²-lactamase

ë¬¸ì œ:
- Carbapenem ë‚´ì„± E. coli, K. pneumoniae ì¦ê°€
- ë¯¸êµ­: CRE (carbapenem-resistant Enterobacteriaceae)
  â†’ ì—°ê°„ 13,000 ê°ì—¼, 1,100 ì‚¬ë§
- í•œêµ­: 2020-2024, NDM-1 ê¸‰ì¦

ëŒ€ì•ˆ:
- Colistin: ë…ì„± ë†’ìŒ (ì‹ ë…ì„±)
- Tigecycline: Bacteriostatic (ì‚´ê·  ì•„ë‹˜)
- Ceftazidime-avibactam: ë¹„ì‹¼, NDMì— ë¬´íš¨

â†’ ìƒˆë¡œìš´ ë©”ì»¤ë‹ˆì¦˜ í•„ìš”
```

**í•´ê²°: MTX-CPP**

```
Why MTX?
- DHFR ì–µì œì œ (ì„¸ê· ë„ ê°€ì§)
- FDA ìŠ¹ì¸ (1953ë…„)
- ì•ˆì „ì„± ë°ì´í„° í’ë¶€

Why CPP?
- 1403 peptide: ì™¸ë§‰ í†µê³¼
- Proline-rich, helical structure
- LPS binding â†’ membrane insertion

ê²°ê³¼:
- E. coli NDM1: MIC 16 Î¼g/mL (ë‹¨ë… MTX >256)
- 15 mg/kg doseë¡œ ë§ˆìš°ìŠ¤ bacteremia ì¹˜ë£Œ
- ë¶€ì‘ìš©: ìµœì†Œ (MTX ë‹¨ë… ëŒ€ë¹„)
```

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**CAMP Therapeutics**:
- ì„¤ë¦½: 2019ë…„ (Seoul National University spin-off)
- CEO: Jaehoon Yu (Ph.D., ì„œìš¸ëŒ€)
- Pipeline: CPP-antibiotic conjugates
- íˆ¬ì: Seed round $5M (2023)

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Choi Y, Choe HW, Kim Y, Yu J* (2024)
"Proline-Hinged Amphipathic Î±-Helical Peptide Targets
 Cardiolipin, Rescuing Eukaryotic Membranes from Influx
 of Anticancer Drugs to Triple-negative Breast Cancer"
J Med Chem. 67: 3385-3399

ê´€ë ¨ì„±: CPP ê¸°ìˆ ì˜ ê¸°ì´ˆ (cancer cellë„ ì™¸ë§‰ ìœ ì‚¬ ì¥ë²½)

ì½ê¸° ì‹œê°„: 40ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

```
1. AMR ìœ„ê¸°ì™€ ê·¸ëŒìŒì„±ê·  ë¬¸ì œ
2. Drug repurposing ì „ëµ
3. MTX ë©”ì»¤ë‹ˆì¦˜ (DHFR ì–µì œ)
4. 1403 CPP ì„¤ê³„ ë° íŠ¹ì„±
5. MTX-CPP conjugate í•©ì„±
6. In vitro efficacy (E. coli, P. aeruginosa)
7. In vivo efficacy (ë§ˆìš°ìŠ¤ bacteremia)
8. Toxicity & PK/PD
9. Clinical development plan
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ê¸°ì¡´ ì•½ë¬¼ë„ CPPì™€ ê²°í•©í•˜ë©´ ìƒˆ ìƒëª…"
- "Carbapenem ë‚´ì„±ê· ì— í¬ë§"
- "FDA ê²½ë¡œ ë‹¨ì¶• ê°€ëŠ¥"

#### ì˜ˆìƒ ì§ˆë¬¸

**Q1**: MTXì˜ ë©´ì—­ì–µì œ íš¨ê³¼ê°€ ê°ì—¼ ì¹˜ë£Œ ì‹œ ë¬¸ì œë˜ì§€ ì•ŠëŠ”ê°€?
**Q2**: CPPì˜ immunogenicityëŠ”? (ë°˜ë³µ íˆ¬ì—¬ ì‹œ)
**Q3**: Resistance ë°œìƒ ê°€ëŠ¥ì„±ì€? (DHFR mutation)

---

### ğŸ”¹ ë°œí‘œ 2 (17:05-17:30): Developing New Antibiotics from Thiopeptide Natural Products

**ì—°ì‚¬**: Hee-Jong Hwang, CEO (A&J Science)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S4-2)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ë°”ë‹¤ ë¯¸ìƒë¬¼ì´ ë§Œë“œëŠ” 'í™© í©íƒ€ì´ë“œ' í•­ìƒì œë¥¼ ì°¾ì•„ì„œ, ë¬¼ì— ì˜ ë…¹ê²Œ ê°œëŸ‰í•˜ë©´, C. difficileê³¼ NTMì„ ì¡ëŠ” ì‹ ì•½ì´ ëœë‹¤"

**ìƒí™©**: C. difficileì˜ ì¬ì•™

```
CDI ì¦ê°€:
- ê³ ë ¹í™”, í•­ìƒì œ ì˜¤ë‚¨ìš©
- ì¬ë°œë¥ : 20-30% (vancomycin í›„)
- ì‚¬ë§ë¥ : 5-10% (ì¤‘ì¦)

ê¸°ì¡´ ì¹˜ë£Œ:
- Vancomycin (ê²½êµ¬): íš¨ê³¼ ìˆì§€ë§Œ ì¬ë°œ
- Metronidazole: íš¨ê³¼ ê°ì†Œ
- Fidaxomicin: ë¹„ìŒˆ ($3,000/course)

ë¬¸ì œ: Broad-spectrum í•­ìƒì œ
â†’ ì •ìƒ ì¥ë‚´ ê· ì´ íŒŒê´´
â†’ C. diff ì¬ì¦ì‹ ê¸°íšŒ

â†’ Narrow-spectrum í•„ìš”
```

**í•´ê²°: Thiopeptides**

```
Micrococcin P2:
- C. difficile MIC: 0.06-0.25 Î¼g/mL
- ì •ìƒ ê· ì´: ì˜í–¥ ì ìŒ
- Ribosome í‘œì  (ë‚´ì„± ì–´ë ¤ì›€)

ê°œì„ :
- ìˆ˜ìš©ì„±: 200,000ë°° â†‘
- GMP ìƒì‚°: decagram scale
- ê²½êµ¬ ì œí˜• ê°œë°œ

â†’ Phase 1 ì¤€ë¹„ (2025-2026)
```

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**A&J Science**:
- ì„¤ë¦½: 2021ë…„
- CEO: Hee-Jong Hwang (Ph.D., UBC)
- ê¸°ìˆ : Marine microbial natural products
- Pipeline: Thiopeptides for CDI, NTM

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Park J, Kim D, Hwang HJ* et al. (2023)
"Identification of Micrococcin P2-Derivatives as
 Antibiotic Candidates Against Two Gram-Positive Pathogens"
J Med Chem. 66: 14265-14277

í•µì‹¬ ë‚´ìš©:
- 200+ Micrococcin analogs
- SAR study
- C. difficile, MRSA activity

ì½ê¸° ì‹œê°„: 50ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

```
1. Thiopeptides ì—­ì‚¬ ë° ì¬ë¶€ìƒ
2. Micrococcin P2 ë°œê²¬ (í•´ì–‘ ë¯¸ìƒë¬¼)
3. Ribosome í‘œì  ë©”ì»¤ë‹ˆì¦˜
4. Structure optimization (ìˆ˜ìš©ì„±, PK)
5. Spectrum (C. diff, MRSA, NTM)
6. Preclinical data (efficacy, toxicity)
7. GMP production (decagram scale)
8. Regulatory strategy (Orphan drug)
9. Clinical development timeline
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ìì—°ì´ ë§Œë“  í•­ìƒì œë¥¼ ê°œëŸ‰"
- "C. difficile ì¬ë°œ ë¬¸ì œ í•´ê²°"
- "NTMì—ë„ íš¨ê³¼ (ë³´ë„ˆìŠ¤)"

#### ì˜ˆìƒ ì§ˆë¬¸

**Q1**: ê²½êµ¬ í¡ìˆ˜ìœ¨ì€? (bioavailability)
**Q2**: Microbiomeì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€? (16S sequencing data)
**Q3**: Thiostreptonê³¼ì˜ ì°¨ë³„ì ì€?

---

### ğŸ”¹ ë°œí‘œ 3 (17:30-17:55): Hinged amphipathic peptides with pH-inducible positive charges against Gram-negative bacteria in infection sites

**ì—°ì‚¬**: Yan Lee, Professor (Seoul National University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S4-3)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ê°ì—¼ ë¶€ìœ„ëŠ” pHê°€ ë‚®ì€ë°, ê·¸ pH ë³€í™”ë¥¼ ê°ì§€í•´ì„œ 'í™œì„±í™”'ë˜ëŠ” í©íƒ€ì´ë“œ í•­ìƒì œë¥¼ ë§Œë“¤ë©´, ì •ìƒ ì¡°ì§ì€ ì•ˆì „í•˜ê³  ì„¸ê· ë§Œ ì£½ì¸ë‹¤"

**ìƒí™©**: Antimicrobial peptidesì˜ ë”œë ˆë§ˆ

```
AMPs (í•­ê·  í©íƒ€ì´ë“œ):
- ì¥ì : ë‚´ì„± ì–´ë ¤ì›€, ê´‘ë²”ìœ„ íš¨ê³¼
- ë‹¨ì : Hemolysis (ì í˜ˆêµ¬ íŒŒê´´), ë…ì„±

ë¬¸ì œ: ì„ íƒì„± ë¶€ì¡±
- ì„¸ê· ë§‰ê³¼ ì¸ê°„ ì„¸í¬ë§‰ ìœ ì‚¬ (lipid bilayer)
- ì–‘ì „í•˜ AMP: ë‘˜ ë‹¤ ê³µê²©

â†’ ì„ íƒì  í™œì„±í™” í•„ìš”
```

**í•´ê²°: pH-Responsive Peptides**

```
KLH3/KLH4:
- Histidine-rich (pKa 6.0)
- pH 7.4: ì¤‘ì„± â†’ ë…ì„± ë‚®ìŒ
- pH 6.5: ì–‘ì „í•˜ â†’ í•­ê·  í™œì„±

ê²°ê³¼:
- Hemolysis: < 5% (pH 7.4)
- A. baumannii killing: > 90% (pH 6.5)
- In vivo: í”¼ë¶€ ê°ì—¼, bacteremia ëª¨ë‘ íš¨ê³¼

â†’ Therapeutic index: 10ë°° í–¥ìƒ
```

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Yan Lee**:
- Professor, Dept of Chemistry, Seoul National Univ.
- ì „ë¬¸: Peptide chemistry, drug delivery
- 2024: Associate Dean (ì—°êµ¬ ë¶€í•™ì¥)

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Seleci M, et al., Lee Y* (2023)
"Selective delivery of protein drug function control of protein drug
 function Choi S, Lee Y, Hwang J, Chun D, Koo H, Lee Y*"
Chem Eng J. 457: 141229

ê´€ë ¨ì„±: pH-responsive delivery system

ì½ê¸° ì‹œê°„: 30ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

```
1. AMPs ê°œìš” ë° í•œê³„
2. pH-responsive ì „ëµ
3. Histidine í™”í•™ (pKa)
4. KLH3/KLH4 ì„¤ê³„
5. In vitro activity (pH ì˜ì¡´ì„±)
6. Hemolysis assay
7. In vivo efficacy (A. baumannii, E. coli)
8. Mechanism (membrane disruption)
9. Future: ë‹¤ë¥¸ stimuli-responsive
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ìŠ¤ë§ˆíŠ¸ í•­ìƒì œ = í•„ìš”í•  ë•Œë§Œ ON"
- "Selectivityê°€ ë…ì„±ì„ ê²°ì •"
- "Precision medicineì˜ ì‹œì‘"

#### ì˜ˆìƒ ì§ˆë¬¸

**Q1**: pH 6.5ëŠ” ëª¨ë“  ê°ì—¼ ë¶€ìœ„ì—ì„œ ë³´ì¥ë˜ëŠ”ê°€?
**Q2**: Protease stabilityëŠ”? (í˜ˆì•¡ ë‚´)
**Q3**: Chronic infection (biofilm)ì—ì„œ pHëŠ”?

---

## ğŸ§  ì„¸ì…˜ í•µì‹¬ ìš”ì•½ (10ê°€ì§€)

1. **ê·¸ëŒìŒì„±ê·  ì™¸ë§‰ = í•­ìƒì œ ê°œë°œ ìµœëŒ€ ë‚œì œ**
2. **CPP technologyë¡œ ê¸°ì¡´ ì•½ë¬¼ ì¬í™œìš© ê°€ëŠ¥**
3. **Thiopeptides = ìŠí˜€ì§„ ë³´ë¬¼, ë‹¤ì‹œ ë¶€ìƒ**
4. **pH-responsive = ê°ì—¼ ë¶€ìœ„ íŠ¹ì´ì  ì¹˜ë£Œ**
5. **Drug repurposingì´ ì‹ ì•½ ê°œë°œë³´ë‹¤ ë¹ ë¥´ê³  ì €ë ´**
6. **ìì—°ë¬¼ (marine microbes)ì—ì„œ ì‹ ê·œ scaffold ë°œêµ´**
7. **Selectivityê°€ ë…ì„±ê³¼ efficacy ëª¨ë‘ ê²°ì •**
8. **Carbapenem ë‚´ì„±ê· ì— í¬ë§ (MTX-CPP)**
9. **C. difficile ì¬ë°œ ë¬¸ì œ í•´ê²° ê°€ëŠ¥ (thiopeptides)**
10. **ì‚°í•™ í˜‘ë ¥ ëª¨ë¸ (CAMP, A&J ë°”ì´ì˜¤í… ì‚¬ë¡€)**

---

## ğŸ¤ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ (30ê°œ)

### ê³¼í•™ì  ì§ˆë¬¸ (10ê°œ)

**Q1-3**: MTX, Thiopeptides, KLH3 ê°ê°ì˜ resistance ë°œìƒ ê°€ëŠ¥ì„±ì€?

**Q4**: CPPì˜ immunogenicityê°€ ë°˜ë³µ íˆ¬ì—¬ ì‹œ ë¬¸ì œë˜ì§€ ì•ŠëŠ”ê°€?

**Q5**: Thiopeptidesê°€ ì •ìƒ ì¥ë‚´ ê· ì´ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€? (Microbiome data)

**Q6**: pH 6.5ê°€ ëª¨ë“  ê°ì—¼ ë¶€ìœ„ì—ì„œ ë³´ì¥ë˜ëŠ”ê°€? (Biofilm ë‚´ë¶€ëŠ”?)

**Q7**: MTX-CPPê°€ ì¸ê°„ ì„¸í¬ì— ì§„ì… ê°€ëŠ¥í•œê°€? (ë…ì„± ìš°ë ¤)

**Q8**: Thiopeptidesì˜ ribosome í‘œì ì´ mitochondrial ribosomeì—ë„ ì˜í–¥?

**Q9**: KLH peptidesê°€ proteaseì— ì˜í•´ ë¶„í•´ë˜ëŠ”ê°€?

**Q10**: 3ê°€ì§€ ì ‘ê·¼ë²•ì„ ë³‘ìš©í•˜ë©´ ì‹œë„ˆì§€ íš¨ê³¼ê°€ ìˆì„ê¹Œ?

### ê¸°ìˆ /ë°©ë²•ë¡  ì§ˆë¬¸ (10ê°œ)

**Q11-13**: MTX-CPP linker cleavage íš¨ìœ¨ì€? Thiopeptides GMP ìˆ˜ìœ¨ì€? KLH peptides í•©ì„± ë¹„ìš©ì€?

**Q14**: CPPì˜ ì™¸ë§‰ í†µê³¼ ë©”ì»¤ë‹ˆì¦˜ ì¦ëª… ë°©ë²•ì€? (í˜•ê´‘, EM?)

**Q15**: Thiopeptides ê²½êµ¬ ì œí˜•ì€? (ìº¡ìŠ, ì •ì œ?)

**Q16**: KLH peptidesì˜ ìµœì  pHëŠ”? (6.0? 6.5? 7.0?)

**Q17**: In vivo PK/PD íŒŒë¼ë¯¸í„°ëŠ”? (Cmax, AUC, half-life)

**Q18**: Resistance selection study í–ˆëŠ”ê°€? (serial passage)

**Q19**: Animal model ì„ íƒ ê¸°ì¤€ì€? (ë§ˆìš°ìŠ¤ ì™¸ ë‹¤ë¥¸ ë™ë¬¼?)

**Q20**: Safety pharmacology study ë²”ìœ„ëŠ”?

### ì‘ìš©/ì‚°ì—… ì§ˆë¬¸ (7ê°œ)

**Q21**: CAMPì˜ MTX-CPP Phase 1 ì‹œê¸°ëŠ”?

**Q22**: A&Jì˜ Thiopeptides FDA orphan drug ì§€ì • ë°›ì•˜ë‚˜?

**Q23**: Seoul Nat'lì˜ KLH peptides ê¸°ìˆ ì´ì „ ê³„íšì€?

**Q24**: ì œì¡° ì›ê°€ëŠ”? (íˆ¬ì—¬ 1íšŒë‹¹)

**Q25**: íŠ¹í—ˆ ìƒí™©ì€? (CPP, Thiopeptides, KLH)

**Q26**: Reimbursement ì „ëµì€? (ë³´í—˜ ì ìš©)

**Q27**: ê¸€ë¡œë²Œ ì‹œì¥ vs. í•œêµ­ ì‹œì¥ ìš°ì„ ìˆœìœ„ëŠ”?

### ì§„ë¡œ ì§ˆë¬¸ (3ê°œ)

**Q28**: ë°”ì´ì˜¤í… ì°½ì—… ì‹œ ê°€ì¥ ì–´ë ¤ìš´ ì ì€?

**Q29**: ëŒ€í•™ ì—°êµ¬ì‹¤ vs. ë°”ì´ì˜¤í… career path?

**Q30**: í¬ë‹¥ì„ CAMP/A&Jì—ì„œ ì±„ìš©í•˜ë‚˜?

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

### Tier 1: CEO/Professor

#### Jaehoon Yu (CAMP Therapeutics)
- ë°”ì´ì˜¤í… ì°½ì—… ê²½í—˜
- CPP technology licensing ê°€ëŠ¥
- í¬ë‹¥/ì—°êµ¬ì› ì±„ìš© ê°€ëŠ¥ì„±

#### Hee-Jong Hwang (A&J Science)
- Marine natural products ì „ë¬¸
- GMP ìƒì‚° ê²½í—˜
- Partnership ê¸°íšŒ

#### Yan Lee (Seoul National University)
- Peptide chemistry ê¶Œìœ„ì
- ê¸°ìˆ ì´ì „ ê²½í—˜
- í•™ìƒ/í¬ë‹¥ ëª¨ì§‘

### Tier 2: ì‚°ì—…ê³„ ì¸ì‚¬

- ì œì•½ì‚¬ BD (business development)
- íˆ¬ìì (VC, angel)
- CRO/CDO (preclinical service)

### Tier 3: ì •ë¶€/ê·œì œ

- MFDS (ì‹ì•½ì²˜) ë‹´ë‹¹ì
- KHIDI (ë³´ê±´ì‚°ì—…ì§„í¥ì›)
- NRF (ì—°êµ¬ì¬ë‹¨) PM

---

## âš¡ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### D-1
- [ ] ë°°ê²½ ìë£Œ 2ì°¨ ì •ë…
- [ ] 3ëª… ì—°ì‚¬ íšŒì‚¬/ì—°êµ¬ì‹¤ ì›¹ì‚¬ì´íŠ¸ í™•ì¸
- [ ] Pipeline, publication íŒŒì•…
- [ ] ëª…í•¨ 30ì¥

### ì„¸ì…˜ ì¤‘
- [ ] í•µì‹¬ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„
- [ ] ì§ˆë¬¸ 2-3ê°œ
- [ ] Networking ëŒ€ìƒ íŒŒì•…

### ì„¸ì…˜ í›„
- [ ] ì—°ì‚¬ ì ‘ê·¼ (ê° 3ë¶„)
- [ ] ëª…í•¨ êµí™˜
- [ ] Follow-up ê³„íš

---

## ğŸ“Š í•™ìŠµ ì„±ê³¼

### ì§€ì‹
- Drug repurposing ì „ëµ ì´í•´
- CPP, Thiopeptides, pH-responsive ë©”ì»¤ë‹ˆì¦˜
- Regulatory pathway (FDA, MFDS)

### ê¸°ìˆ 
- Conjugation chemistry
- Natural product optimization
- Peptide design

### íƒœë„
- ì‚°í•™ í˜‘ë ¥ ê°€ì¹˜
- ì°½ì—… ê°€ëŠ¥ì„±
- ë²ˆì—­ ì—°êµ¬ (bench-to-bedside)

### ë„¤íŠ¸ì›Œí¬
- CEO 2ëª…, Professor 1ëª…
- ë°”ì´ì˜¤í… ì—…ê³„ ì§„ì…ì 
- íˆ¬ìì/CRO ì ‘ì 

---

**ë¬¸ì„œ ì‘ì„±**: 2025-10-29
**ë²„ì „**: 2.0
**í•™íšŒ**: IAMRT 2025

**ì´ ì„¸ì…˜ì€ 'ì‹¤ì œ ì‹ ì•½ ê°œë°œ'ì„ ë‹¤ë£¹ë‹ˆë‹¤. í¬ë‹¥/ì‚°ì—… ì§„ë¡œì— ì§ì ‘ ë„ì›€ë©ë‹ˆë‹¤!**

**Good luck! ğŸ‰ğŸ”¬ğŸ’Š**